title: Circulating humanin levels are associated with preserved coronary endothelial function.
abstract: Humanin is a small endogenous antiapoptotic peptide, originally identified as protective against Alzheimer's disease, but subsequently also found on human endothelium as well as carotid artery plaques. Endothelial dysfunction is a precursor to the development of atherosclerotic plaques, which are characterized by a highly proinflammatory, reactive oxygen species, and apoptotic milieu. Previous animal studies demonstrated that humanin administration may improve endothelial function. Thus the aim of this study was to test the hypothesis that patients with coronary endothelial dysfunction have reduced systemic levels of humanin. Forty patients undergoing coronary angiography and endothelial function testing were included and subsequently divided into two groups based on coronary blood flow (CBF) response to intracoronary acetylcholine (normal ≥ 50% increase from baseline, n = 20 each). Aortic plasma samples were obtained at the time of catheterization for the analysis of humanin levels and traditional biomarkers of atherosclerosis including C-reactive protein, Lp-Pla(2), and homocysteine. Baseline characteristics were similar in both groups. Patients with coronary endothelial dysfunction (change in CBF = -33 ± 25%) had significantly lower humanin levels (1.3 ± 1.1 vs. 2.2 ± 1.5 ng/ml, P = 0.03) compared with those with normal coronary endothelial function (change in CBF = 194 ± 157%). There was a significant and positive correlation between improved CBF and humanin levels (P = 0.0091) not seen with changes in coronary flow reserve (P = 0.76). C-reactive protein, Lp-Pla(2), and homocysteine were not associated with humanin levels. Thus we observed that preserved human coronary endothelial function is uniquely associated with higher systemic humanin levels, introducing a potential diagnostic and/or therapeutic target for patients with coronary endothelial function.
authors.affiliation: Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and College of Medicine, Rochester, Minnesota 55905, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Widmer
authors.forename: A J
authors.initials: AJ
authors.lastname: Flammer
authors.forename: J
authors.initials: J
authors.lastname: Herrmann
authors.forename: M
authors.initials: M
authors.lastname: Rodriguez-Porcel
authors.forename: J
authors.initials: J
authors.lastname: Wan
authors.forename: P
authors.initials: P
authors.lastname: Cohen
authors.forename: L O
authors.initials: LO
authors.lastname: Lerman
authors.forename: A
authors.initials: A
authors.lastname: Lerman
mesh_terms: D000109:Acetylcholine; D000328:Adult; D050197:Atherosclerosis / Q000097:blood / Q000503:physiopathology; D015415:Biomarkers; D001774:Blood Chemical Analysis; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000502:physiology; D003327:Coronary Disease / Q000503:physiopathology*; D003331:Coronary Vessels / Q000502:physiology* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D004730:Endothelium, Vascular / Q000502:physiology*; D005260:Female; D006333:Heart Failure / Q000503:physiopathology; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000097:blood; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism* / Q000502:physiology*; D008055:Lipids / Q000097:blood; D008297:Male; D008833:Microcirculation / Q000502:physiology; D008875:Middle Aged; D014665:Vasodilator Agents
chemical_list: D015415:Biomarkers; D047908:Intracellular Signaling Peptides and Proteins; D008055:Lipids; D014665:Vasodilator Agents; C427211:humanin; D000109:Acetylcholine